This clinical trial evaluates tumor tissue and lymph nodes near the tumor removed during surgery in patients with kidney cancer. Kidney cancer is among the top ten most common cancers in both men and women. There have been many new personalized systemic therapies for kidney cancer. However, despite initial response, resistance usually develops within a year. Studying tumor tissue and draining lymph node samples from patients with kidney cancer in the laboratory may help doctors to better understand how certain immune cells (called T cells) from the tumor and the regional and draining lymph nodes behave and fight cancer. This may help find better ways to detect, treat, and understand kidney cancer and related diseases.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07038733.
Locations matching your search criteria
United States
Connecticut
New Haven
Yale UniversityStatus: Active
Contact: David A Braun
Phone: 203-200-6622
PRIMARY OBJECTIVES:
I. To collect and perform molecular analyses on tumor and draining lymph node tissue from patients with kidney cancers.
II. To understand the biology of human kidney cancers, their responses to anti-cancer therapies, mechanisms of resistance.
III. To predict toxicities from those therapies.
OUTLINE:
Patients receive (ICG) injection into tumor tissue and undergo surgical removal of draining lymph nodes and regional lymph nodes during standard of care surgery. Additionally, patients undergo blood sample collection during surgery.
After completion of study intervention, patients are followed for up to 24 months after surgery.
Trial PhaseNo phase specified
Trial Typebasic science
Lead OrganizationYale University
Principal InvestigatorDavid A Braun
